Tripathi Shashank, Kaushik Meenakshi, Dwivedi Rekha, Tiwari Prabhakar, Tripathi Manjari, Dada Rima
Department of Biostatistics and Medical Informatics, University College of Medical Sciences (UCMS) & GTB hospital, New Delhi, India.
Department of Anatomy, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
J Alzheimers Dis Rep. 2024 Oct 18;8(1):1422-1433. doi: 10.1177/25424823241289039. eCollection 2024.
Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are progressive neurodegenerative disorders, and probiotics may offer therapeutic benefits by modulating gut microbiota and reducing inflammation.
This study systematically evaluated the impact of probiotics on cognitive function in MCI and AD through a meta-analysis of randomized controlled trials (RCTs).
A systematic review and meta-analysis were performed following PRISMA 2020 guidelines. PubMed, Embase, EBSCO, and Cochrane databases were searched for RCTs (January 2000-January 2024) on probiotic interventions lasting 8-24 weeks. Cognitive outcomes included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), language, naming, visual-spatial, memory, and attention. Data were analyzed using R with a random-effects model to calculate pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs). Risk of bias was rigorously assessed.
Out of 2000 articles, 500 full texts were screened, and 10 studies were included. The meta-analysis showed varied effect sizes: MMSE (SMD: 0.28, 95%CI -0.35-0.91, p = 0.38), MoCA (SMD: 0.51, 95%CI -0.49-1.52, p = 0.33), language (SMD: -0.12, 95% CI -0.54-0.29, p = 0.56), naming (SMD: 0.02, 95%CI -0.69-0.74, p = 0.95), visual-spatial (SMD: 0.38, 95%CI -0.13-0.88, p = 0.14), memory (SMD: 0.20, 95%CI -0.15-0.55, p = 0.26), and attention (SMD: -0.07, 95%CI -0.44-0.30, p = 0.71). Positive SMDs suggest cognitive improvement, while non-significant negative SMDs indicate trends toward decline, inclined by probiotic strains, duration, and participant characteristics.
Probiotics did not significantly improve cognitive function in MCI and AD patients, with variability in effects across cognitive domains, suggesting the need for tailored interventions and future studies.
轻度认知障碍（MCI）和阿尔茨海默病（AD）是进行性神经退行性疾病，益生菌可能通过调节肠道微生物群和减轻炎症发挥治疗作用。
本研究通过对随机对照试验（RCT）的荟萃分析，系统评估益生菌对MCI和AD患者认知功能的影响。
按照PRISMA 2020指南进行系统评价和荟萃分析。检索PubMed、Embase、EBSCO和Cochrane数据库，查找2000年1月至2024年1月期间持续8 - 24周的益生菌干预RCT。认知结局包括简易精神状态检查表（MMSE）、蒙特利尔认知评估量表（MoCA）、语言、命名、视觉空间、记忆和注意力。使用R软件采用随机效应模型分析数据，计算合并标准化均数差（SMD）及95%置信区间（CI）。严格评估偏倚风险。
在2000篇文章中，筛选出500篇全文，纳入10项研究。荟萃分析显示效应大小各异：MMSE（SMD：0.28，95%CI -0.35 - 0.91，p = 0.38）、MoCA（SMD：0.51，95%CI -
